Co-Diagnostics, Inc. Secures Dismissal of Class-Action Lawsuit

Co-Diagnostics, Inc, a leading molecular diagnostics company, has announced that the class-action lawsuit filed against the company has been dismissed. The ruling marks a significant legal victory, reinforcing Co-Diagnostics’ confidence in its business practices and commitment to delivering innovative diagnostic solutions.

The lawsuit, which alleged securities-related claims, was dismissed in its entirety, underscoring the company's adherence to regulatory and corporate governance standards. Co-Diagnostics has consistently maintained its dedication to transparency, scientific integrity, and investor confidence.

“We are pleased with the court’s decision to dismiss the lawsuit, validating our position and allowing us to focus on our mission of advancing molecular diagnostics,” said Dwight Egan, CEO of Co-Diagnostics. “Our priority remains developing cutting-edge technology that improves global healthcare outcomes.”

Co-Diagnostics continues to expand its portfolio of innovative molecular testing solutions, addressing critical healthcare challenges worldwide. With the dismissal of the lawsuit, the company remains committed to driving scientific advancements and enhancing shareholder value.